您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

SCITEK INTERNATIONAL (H.K.) LIMITED
Email: sciteck.hongkong@gmail.com
 

当前本网站药物产品种数共 8524 处方药 8148 非处方药 269 保健品/医疗用具 107

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 日本药房
产地国家: 日本
所属类别: 心血管系统药物->治疗心衰药物
处方药:处方药
包装规格: 10毫克/10毫升/瓶 5瓶/盒
计价单位:
  点击放大  
生产厂家中文参考译名:
安斯泰来
生产厂家英文名:
Astellas
该药品相关信息网址1:
http://www.astellas.com/
原产地英文商品名:
Milrila 10mg/10ml/vial 5vials/box
原产地英文药品名:
Milrinone
原产地英文化合物名称:
1,6-Dihydro-2-methyl-6-oxo-[3,4'-bipyridine]-5-carbonitrile
中文参考商品译名:
Milrila 10毫克/10毫升/瓶 5瓶/盒
中文参考药品译名:
米力农
中文参考化合物名称:
2-甲基-6-氧-1,6-二氢-[3,4’双吡啶]-5甲腈
原产地国家批准上市年份:
0000/00/00
英文适应病症1:
Inotropic
英文适应病症2:
Vasodilating
英文适应病症3:
Chronic heart failure
英文适应病症4:
Congestive Heart Failure
临床试验期:
完成
中文适应病症参考翻译1:
增强心肌收缩力
中文适应病症参考翻译2:
扩张血管
中文适应病症参考翻译3:
慢性心力衰竭
中文适应病症参考翻译4:
充血性心力衰竭
药品信息:

---------------------------------------------------------------
 部分中文Milrila处方资料(仅供参考)
---------------------------------------------------------------

Milrinone米力农

别名:1,6-Dihydro-2-methyl-6-oxo-[3,4'-bipyridine]-5-carbonitrile; Corotrope; Milrila。2-甲基-6-氧-1,6-二氢-[3,4’双吡啶]-5甲腈。

所属类别:药物,心脑血管药物,强心药

用途:
    强心药,具有增强心肌收缩力和直接扩张血管的作用
    新型非苷类非儿茶酚胺类强心药,作用与氨吡酮相似,正性肌力作用强,约为氨力农的20~50倍,并有明显的扩张血管平滑肌作用,能降低心脏负荷,还能极好地改善肾脏和肌肉供血。口服和静脉均有效,无严重不良反应。用于慢性心力衰竭及充血性心力衰竭等严重的心力衰竭。

米力农注射液
    米力农注射液磷酸二酯酶抑制剂,为氨力农的同类药物,作用机理与氨力农相同,兼有正性肌力作用和血管扩张作用。本品正性肌力作用主要是通过抑制磷酸二酯酶,使心肌细胞内环磷酸腺苷(CAMP)浓度增高,细胞内钙增加,心肌收缩力加强,心排血量增加。而与肾上腺素b1受体或心肌细胞Na+、K+ -ATP酶无关其血管扩张作用可能是直接作用于小动脉或所致,从而可降低心脏前、后负荷,降低左心室充盈压,改善左室功能,增加心脏指数,但对平均动脉压和心率无明显影响。本品对伴有传导阻滞的患者较安全。本品口服时不良反应较重,不宜长期应用。

药代动力学
  静脉给药5~15分钟起生效,清除半衰期为2~3小时。蛋白结合率70%。

作用与用途
  本品可使高血性心力衰竭患者体循环血管阻力、肺动脉平均压和肺毛细血管楔嵌压显著降低、心输出量、心脏指数和每搏指数增加,但不增加心肌耗氧量。   
    适用于充血性心力衰竭短期静脉用药。

用法
  可用适量生理盐水或葡萄糖液稀释后,先按37.5μg/kg-50μg/kg缓慢静脉注射10分钟(注射过快,可能出现室性早搏),继续以0.375μg~0.75μg/kgmin静脉滴注,此后根据临床效应调整用量。

副作用
  少数病人可有低血压、窦性心动过速、室性心律失常、血小板计数减少、肝、肾功能异常、及头痛、头晕、恶心、呕吐等。

药物相互作用
  与常用强心药、利尿药、血管扩张药合用,临床未见不良相互作用,与多巴胺、多巴酚丁胺合用有协同作用。

禁忌症
  严重室性心律失常。对本品过敏者。

注意事项
①用药期间应监测心电图,心率及血压,必要时调整用量。   
②本品有较强的血管扩张作用,严重低血压或血容量不足者应慎用。   
③不宜用于重度辨膜狭窄症。   
④可能加重肥厚性心肌病的流出道梗阻。   
⑤合并用强利尿药时,应注意纠正血容量不足与电介质平衡。   
⑥对房颤或房扑患者,本品可增加房室传导、导致心室率增快,宜先用或联合应用控制心室率的药物。   
⑦肝肾功能损害严重者慎用。   
⑧尚无用于孕妇哺乳及儿童的经验,使用时权衡利弊。   
⑨用药期间应监测血小板计数。

Milrila - General Information:
A positive inotropic cardiotonic agent with vasodilator properties. It inhibits cAMP phosphodiesterase activity in myocardium and vascular smooth muscle. Milrila is a derivative of amrinone and has 20-30 times the ionotropic potency of amrinone.

Pharmacology:
Milrila, a synthetic dimethylxanthine derivative structurally related to theophylline and caffeine, is used in the treatment of peripheral vascular diseases and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy.

Milrila Interactions:
No untoward clinical manifestations have been observed in limited experience with patients in whom PRIMACOR was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements.

Chemical Interactions

There is an immediate chemical interaction which is evidenced by the formation of a precipitate when furosemide is injected into an intravenous line of an infusion of PRIMACOR. Therefore, furosemide should not be administered in intravenous lines containing PRIMACOR.

Milrila Contraindications:
PRIMACOR is contraindicated in patients who are hypersensitive to it.

Additional information about Milrila:
Milrila Indication: Indicated for the treatment of congestive heart failure.
Mechanism Of Action: Milrila inhibits erythrocyte phosphodiesterase, resulting in an increase in erythrocyte cAMP activity. Subsequently, the erythrocyte membrane becomes more resistant to deformity. Along with erythrocyte activity, Milrila also decreases blood viscosity by reducing plasma fibrinogen concentrations and increasing fibrinolytic activity.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Milrinone
Synonyms: Milrinone Lactate
Drug Category: Vasodilator Agents; Cardiotonic Agents
Drug Type: Small Molecule; Approved
Other Brand Names containing Milrinone: Corotrop; Corotrope; Milrila; Primacor;
Absorption: Milrinone is rapidly and almost completely absorbed after oral administration. Bioavailability is 92% (in healthy volunteers).
Toxicity (Overdose): LD50 = 0.3 mg/L in rats
Protein Binding: 70 to 80%
Biotransformation: There are five metabolites but the O-glucuronide represents the major pathway of biotransformation.
Half Life: 2.3 hours
Dosage Forms of Milrila: Solution Intravenous
Liquid Intravenous
Chemical IUPAC Name: 6-methyl-2-oxo-5-pyridin-4-yl-1H-pyridine-3-carbonitrile
Chemical Formula: C12H9N3O
Organisms Affected: Humans and other mammals

---------------------------------------------------------------

更新日期: 2013-03-26
附件:
 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:sciteck.hongkong@gmail.com, 15901965168@163.com